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Design of the study
The study was a placebo-controlled, single blind, randomized therapeutic trial in men and women aged 30-69 years with diastolic pressures (phase 5 diastolic blood pressure) ranging from 95 to 109 mmHg. All subjects were free of evidence of target organ damage. Subjects were admitted according to the mean of four diastolic readings over two screening visits and were randomly assigned to active or placebo groups. Commencing in July 1973, 103 643 subjects were screened and 3943 entered the study, which was conducted in four centres. Tablets, active or placebo, were commenced at a third visit if diastolic pressure was again 1 9 5 mmHg. However, if it was (95 mmHg at this visit, tablets were withheld but the subjects continued to be observed, as for those taking tablets, at 4 months intervals. Subsequently, if diastolic pressure rose to 95 mmHg or more, tablets were commenced according to the original assigned randomized group. This report concerns the 3323 subjects who commenced taking tablets.
Chlorothiazide was used as the first order drug for all patients. Other drugs added to the regimen as necessary where emethyldopa, propranolol, pindolol, hydrallazine or clonidine.
Trial endpoints (TEP) were defined by protocol in the categories: deaths from all causes; cerebrovascular disease, including transient ischaemic attacks with observed neurological signs; acute and chronic coronary heart disease; retinopathy; certain other arterial diseases and renal failure.
Tablets were prescribed with the general objective to reduce diastolic pressure to 80 mmHg. Subjects whose pressures rose above defined mild limits (185, all but two in the placebo group) were placed on definitive medication and continued under observation. Trial endpoints which occurred in such subjects were counted against their original randomized regimen. Thus the study was a comparison of two management regimens, one in which drug treatment was prescribed from time of diagnosis (i.e. the active group) and the other in which surveillance was maintained from time of diagnosis, but definitive drug therapy was added if pressures rise above mild limits (the placebo group). Screening methods and study design have been previously reported by Abernethy (1974) .
A sequential comparison of the numbers of TEP occurring in the active and placebo treatment groups was reported throughout the study, to an ethics committee, the management committee being unaware of the results. In October 1978 the management committee was told that there were certain trends in the number of TEP that were dflerentiating the groups, but the difference in numbers was not sufficient to pose an ethical problem. On the basis of these comments, the management committee determined that the trial should continue, but a comparison of TEP rates based on analysis of survivial by the Cox method, should be undertaken, using results as of 26 October 1978. It considered these results in March 1979, and having regard for the occurrence of additional TEP reported between October 1978 and March 1979 it decided that 5 March 1979 should be the final censoring date. The decision to stop the trial was thus made as a result of a single comprehensive analysis. This paper reports the results as at the 26 October 1978, when the average follow-up period was 3 years and 8 months.
Analysis for this Report has been made by the 'on treatment' approach, i.e. by counting TEP only if they occurred while the subject was continuing randomized regimen or within 4 months of stopping. Analysis has also been made by the 'intention to treat' approach, in which TEP up to the censoring date are counted whether occurring on randomized treatment or after prematurely stopping.
Results
Subjects in the active and placebo groups were well matched in relation to age, sex, weight, entry blood pressure and risk factors for coronary heart disease.
The status of the trial population at the October 1978 censoring date is shown in Table 1 . There were 2850 (85.8%) subjects under observation, who had not experienced a TEP. Of these 787 had prematurely stopped their randomized regimen. There were 239 (7.2%) with TEP, of whom 53 had experienced the TEP after prematurely stopping. The status of 234 subjects (7.0%) was unknown.
The possibility of bias in the results of large therapeutic trials arises from subjects prematurely stopping the regimen to which they were randomized, or from those whose status is unknown at the censoring date. The active and placebo subjects in this study who stopped prematurely were well matched in relevant criteria at entry. Although there were more subjects in the placebo group prematurely stopping, analysis of the reasons for stopping and the numbers of TEP occurring after stopping do not suggest that bias in the conclusions of this paper have arisen from this source. The numbers of subjects lost to follow-up were not significantly different in the active and placebo groups and also showed no significant difference in entry characteristics. Bias does not appear to have arisen from this source, but the matter will be clearer when the programme to retrieve 'lost to follow-up' subjects is complete at the final censoring date.
The numbers of TEP and rates per 1000 person years of exposure to risk are shown in Table 2 . There were significantly fewer events, both fatal (P < 0.05) and non-fatal (P < 0.05) in the active treatment group. Inspection of relevant covariates which might interact with treatment effect showed that the difference in TEP rates was strongly related to the level of entry diastolic pressure (considered in 5 mmHg classes) and the benefit of treatment was predominantly due to its effect in subjects with entry diastolic pressure 1 100 mmHg.
In Table 3 the numbers and rates are shown for TEP grouped in the clinical categories of acute myocardial infarction and cerebrovascular disease. Again the lower rates in the actively treated subjects were predominantly due to treatment effects in subjects with entry diastolic pressure 2 100 mmHg.
Blood pressure control
We have taken as an index of blood pressure control for each subject the average of all pressure readings, taken throughout the trial after commencing tablets. Diastolic blood pressure fell in both active and placebo groups, the mean fall being 26.1 and 20.0 mmHg respectively for the class with the highest entry pressures ( 2 115 mmHg) and 8.9 and 4.9 mmHg for the class with lowest entry pressures (95-99 mmHg). It is emphasized that although entry into the study was limited to subjects with mean diastolic 95-109 mmHg, at the third or entry visit, pressures ranged more widely. The difference between the active and placebo subjects through the trial ranged from 7.1 for highest, to 4.1 for lowest entry pressure classes.
Discussion and conclusions
The analysis for this report was by the 'on treatment' approach. Analysis for the 'intention to treat' approach showed comparably favourable effects of active treatment at similar levels of significance.
The difference in TEP rates between active and placebo subjects with entry diastolic pressure 1 1 0 0 mmHg indicates that at that level treatment prevented approximately nine hypertensive complications, three of which were deaths, per 1000 persons treated per year over the period The benefit of treatment in respect to non-fatal TEP other than coronary heart disease and to fatal blood pressure-related deaths were similar to those reported by the Veteran's Administration (VA) Cooperative Study (1970). The incidence of TEP in that study, however, for both active and placebo groups, were considerably higher than that in the present study, probably reflecting the more severe levels of hypertensive disease at entry in the VA subjects. In respect to acute myocardial infarction the present results differ from the VA study, which showed no significant difference in the incidence between the active and placebo subjects. In view of the higher incidence of acute myocardial infarction of follow-up.
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Therapeutic Trial Reporr in our actively treated subjects with entry diastolic pressure < 100 mmHg, even though the dfierence was not statistically significant, it would be prudent to await the final results of our study before drawing conclusions about this aspect of the results.
This Australian study was designed and the numbers of subjects were calculated to test the hypothesis that pharmacological treatment would reduce deaths by 30%. The study was stopped because the results confirmed this at the required confidence level (P < 0.05). The numbers in the study were not calculated to permit detailed analyses of treatment effects on particular TEP or in subsets of the trial population. It was tempting to continue the study to accumulate more trial endpoints in these subcategories, but it was clearly unethical to do so. Nevertheless, the results showed that the trend of benefit was apparent in both men and women, and in subjects over 50 and under 50 years of age.
We conclude that, as a general principle, pharmacological treatment should be instituted in subjects with diastolic pressures of 100 mmHg or more, as determined according to our screening procedure, whereas subjects with diastolic pressures of 95-99 mmHg do not require pharmacological therapy but should be kept under periodic observation.
